Sales and Marketing

Showing 15 posts of 11528 posts found.

eye

All eyes on dry eye disease

May 8, 2018 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing TopiVert, dry eye disease, eye, pharma

Dr Matthew Fyfe, Head of Chemistry and Intellectual Property at TopiVert, gives an illuminating look into the latest developments in …
novartis_side_building

FDA approves Novartis combo in rare thyroid cancer subtype

May 8, 2018 Manufacturing and Production, Sales and Marketing Cancer, FDA, Tafinlar, mekinist, thyroid cancer

The FDA has announced its decision to approve the use of Novartis’ combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in …
jj

J&J’s ketamine-based antidepressant showed mixed success at Phase 3

May 8, 2018 Manufacturing and Production, Research and Development, Sales and Marketing J&J, JJ, Johnson & Johnson, Ketamine, antidepressant, depression, esketamine, pharma

Johnson & Johnson has revealed new data on its new depression drug esketamine, its chemically ‘left-handed’ version of the controlled …

Genmab and Janssen’s Darzalex combo scores FDA approval in multiple myeloma

May 8, 2018 Manufacturing and Production, Sales and Marketing FDA, Genmab, Janssen, US, darzalex, multiple myeloma, pharma

Genmab and Janssen have revealed that their combination of Darzalex (daratumumab) with bortezomib (Velcade), melphalan, and prednisone (VMP) has received …
astrazeneca_sign_sky

AstraZeneca jettisons schizophrenia drug for $538 million

May 8, 2018 Manufacturing and Production, Sales and Marketing AstraZeneca, Luye Pharma, Seroquel, pharma, schizophrenia

AstraZeneca has confirmed it has signed a deal to jettison its schizophrenia drug Seroquel and its extended release version Seroquel …
takeda_global_hq

It’s official: Takeda to buy Shire for £46 billion

May 8, 2018 Manufacturing and Production, Sales and Marketing Shire, Takeda, acquisition, pharma

After more than a month of uncertainty, Takeda has finally confirmed it has managed to successfully acquire Shire, agreeing on …
top_ten

Top Ten most popular articles on Pharmafile.com this week

May 4, 2018 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, EMA, Kymriah, Novartis, Porton Biopharma, Regeneron, Roche, Sandoz, Sanofi, Shire, Takeda, biosimilars, dementia

It’s Friday again and it’s been a week busy with companies’ financials. One company’s in particular were of note due …
opioid_therapy_credit_-_us_air_force_valerie_monroy

Los Angeles becomes latest US city to sue pharma over opioid crisis

May 4, 2018 Medical Communications, Sales and Marketing Los Angeles, opioid crisis, pharma

The city of Los Angeles has levied legal action against a number of pharmaceutical firms for their role in advancing …
baby-784607_960_720

Mallinckrodt gets two thumbs down from FDA for jaundice drug

May 4, 2018 Medical Communications, Sales and Marketing InfaCare, Mallinckrodt, biotech, drugs, pharma, pharmaceutical

Mallinckrodt paid $80 million, with a further $345 million dependent on milestones, to acquire InfaCare in the hope that the …
bms

BMS looks to leverage real-world data, with Flatiron collab

May 3, 2018 Medical Communications, Sales and Marketing Bristol-Myers Squibb, Flatiron health, biotech, drugs, pharma, pharmaceutical

Bristol-Myers Squibb has extended its existing collaboration with Flatiron Health by three years and expanded the efforts both will be …
sugar_tax

The UK sugar tax: A sweet or sour move?

May 3, 2018 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing UK, obesity, pharma, sugar tax

Dr Daniel Bailey, Senior Lecturer in Health, Nutrition and Exercise at the University of Bedfordshire, discusses the benefits of the …

Sandoz US woes continue with biosimilar rejection

May 3, 2018 Sales and Marketing Novartis, Sandoz, biosimilars, biotech, drugs, pharma, pharmaceutical

In Novartis’ recently released Q1 results, which largely beat analysts’ estimates, Sandoz was a black spot on its record – …
20170628182643b6d1090b2-8235-4860-8281-743f52e15ed4

Samsung BioLogics’ shares down $6bn after accounting furore

May 2, 2018 Research and Development, Sales and Marketing Samsung BioLogics, Samsung Bioepis, biotech, drugs, pharma, pharmaceutical, south korea

Samsung BioLogics’ shares have been hit hard, after the South Korean company was handed a notice of suspected breach of …
novartis_window

Novartis becomes first to gain second CAR T indication

May 2, 2018 Research and Development, Sales and Marketing Gilead, Kymriah, Novartis, Yescarta, biotech, drugs, pharma, pharmaceutical

Novartis has announced that its CAR T treatment, Kymriah, has successfully been given a second indication for the treatment of …
The Gateway to Local Adoption Series

Latest content


Five Facts about COPD

October 11, 2026